Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Felbamate in refractory partial epilepsy.

R Canger1, A Vignoli, R Bonardi

  • 1Epilepsy Regional Centre, San Paolo Hospital, University of Milan, School of Medicine, Italy. crehsp@imiucca.csi.unii.it

Epilepsy Research
|April 8, 1999
PubMed
Summary

Felbamate (FBM) add-on therapy effectively reduced seizure frequency in patients with drug-refractory partial epilepsy. While not all patients became seizure-free, many experienced significant seizure reduction with a generally well-tolerated safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center.

Epilepsy & behavior : E&B·2023
Same author

Seizure outcome after epilepsy surgery in tuberous sclerosis complex: Results and analysis of predictors from a multicenter study.

Journal of the neurological sciences·2021
Same author

Electro-clinical and neurodevelopmental outcome in six children with early diagnosis of tuberous sclerosis complex and role of the genetic background.

Italian journal of pediatrics·2020
Same author

PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status.

Thrombosis research·2016
Same author

PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN).

Thrombosis research·2016
Same author

Coagulation and cancer: biological and clinical aspects.

Journal of thrombosis and haemostasis : JTH·2013

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Epilepsy is a chronic neurological disorder characterized by recurrent seizures.
  • Drug-refractory epilepsy often requires exploring alternative therapeutic options.
  • Partial epilepsy accounts for a significant proportion of epilepsy cases.

Purpose of the Study:

  • To evaluate the efficacy and safety of Felbamate (FBM) as an add-on therapy.
  • To assess FBM's impact on seizure frequency in patients with drug-refractory partial epilepsy.

Main Methods:

  • An open-label study was conducted with 36 patients diagnosed with drug-refractory partial epilepsy.
  • Felbamate (FBM) was gradually titrated, with a mean daily maintenance dose of 1936 mg.
  • Patients were monitored clinically, with regular laboratory tests, over a mean follow-up of 10 months.

Related Experiment Videos

Main Results:

  • 5% of patients achieved complete seizure freedom.
  • 11% of patients experienced a seizure reduction exceeding 75%.
  • 23% of patients demonstrated a 50-75% decrease in seizure frequency (P = 0.0001).
  • Common adverse events included nausea, vomiting, anorexia, and weight loss.

Conclusions:

  • Felbamate (FBM) demonstrates efficacy in managing drug-refractory partial epilepsy.
  • The add-on therapy shows a relatively well-tolerated safety profile despite a small patient sample.
  • Further investigation may be warranted to optimize FBM use in specific epilepsy populations.